HOME >> MEDICINE >> NEWS
Research improves treatment of bladder cancer

COLUMBUS, Ohio - Researchers have found a relatively simple way to dramatically improve the cancer-killing capacity of a drug often used to treat superficial bladder cancer.

The changes nearly doubled the number of people who were cancer-free after five years, compared to those receiving the standard therapy, and lengthened the time before tumors recurred in these patients.

The finding is the result of a five-year, international study published in the April 18 issue of the Journal of the National Cancer Institute.

The study looked at ways to improve the use of mitomycin C (MMC) following surgical removal of the tumor. In both the standard and the experimental therapy, MMC is placed in the bladder where it is held by the patient for about two hours.

The new therapy, however, took special measures to maintain a high drug concentration in the bladder.

"We compared the usual way of giving the drug to a new approach, said Jessie L-S Au, distinguished university professor and Dorothy M. Davis Chair in Cancer Research at the College of Pharmacy at Ohio State University.

Patients receiving the experimental treatment went an average of 29.1 months before their cancer recurred, while those receiving the standard treatment had recurrence in 11.3 months.

There was also a statistically significant difference in the number of patients who were recurrence-free after five years: 42.6 percent in the modified treatment versus 23.5 receiving standard treatment.

"We have found a way to make this treatment more effective in a highly significant way," said Au, a researcher with Ohio State's Comprehensive Cancer Center. "We nearly doubled the percentage of patients who were disease-free after five years."

The study, done by Au and a team of researchers, involved 230 patients with confirmed superficial bladder cancer who were at high risk of recurrence. Of these, 111 patients received standard treatment and 119 received the experimental
'"/>

Contact: Jessie L-S Au
Au.1@osu.edu
614-292-4244
Ohio State University
17-Apr-2001


Page: 1 2

Related medicine news :

1. Researchers search for first sign of congestive heart failure
2. Research offers hope of new treatments for liver damage
3. Research suggests possible blood test for multiple sclerosis
4. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
5. 2005 Award for Basic Research in Biological Mineralization
6. 2005 Craniofacial Biology Research Award
7. 2005 Research in Dental Caries Award
8. 2005 Research in Prosthodontics and Implants Award
9. 2005 Basic Research in Periodontal Disease Award
10. 2005 Research in Oral Biology Award
11. 2005 Pulp Biology Research Award

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... December 08, 2016 , ... ... distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in ... and patient safety. Only a few hospitals and facilities have earned this distinction. ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick Taché ... Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is a ... & Medical Technology Group have been featured speakers at every DeviceTalks conference since 2011. ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it had joined the ... as a non-profit organization to unite pharmaceutical and healthcare companies that share a ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are ... this in mind, SIGVARIS has created a new line of anti-embolism stockings to ... and provide the benefits of graduated compression when transitioning from recovery to early ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...
(Date:12/8/2016)... -- Global Interventional Radiology Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...
(Date:12/8/2016)... Dec. 8, 2016  Eli Lilly and Company (NYSE: ... its phase 3 EXPEDITION3 trial at the 9 th ... previously disclosed, solanezumab did not meet the primary endpoint ... initiated in people with mild dementia due to Alzheimer,s ... for solanezumab for the treatment of mild dementia due ...
Breaking Medicine Technology:
Cached News: